Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors

Clinical Cancer Research

Volumn 11, Issue 11, 2005, Pages 4198-4203

  Onuma, Etsuro ^a   Azuma, Yumiko ^a   Saito, Hidemi ^a   Tsunenari, Toshiaki ^a   Watanabe, Toshihiko ^b   Hirabayashi, Manabu ^b   Sato, Koh ^a   Yamada Okabe, Hisafumi ^a   Ogata, Etsuro ^c  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN DERIVATIVE; CALCIUM; ELCATONIN; NEUTRALIZING ANTIBODY; PARATHYROID HORMONE RELATED PROTEIN; PARATHYROID HORMONE RELATED PROTEIN ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMORAL HYPERCALCEMIA OF MALIGNANCY; HYPERCALCEMIA; KIDNEY TUBULE ABSORPTION; MALE; MOUSE; NONHUMAN; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RELAPSE; TREATMENT OUTCOME; TUMOR XENOGRAFT;

ALENDRONATE; ANIMALS; ANTIBODIES, MONOCLONAL; BONE RESORPTION; CALCITONIN; CALCIUM; CELL LINE, TUMOR; DIPHOSPHONATES; DRUG RESISTANCE; HUMANS; HYPERCALCEMIA; KIDNEY; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; PARATHYROID HORMONE; PARATHYROID HORMONE-RELATED PROTEIN; RATS; RATS, INBRED F344; RATS, NUDE; TIME FACTORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 20344397444     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-2531     Document Type: Article

References (18)

1. Ralston SH, Gallacher SJ, Patel U, Campbell J, Boyle IT. Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients. Ann Intern Med 1990;112:499-504.
2. Fleisch H. Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 1991;42: 919-44.
3. Body JJ, Louviaus I, Dumon JC. Decreased efficacy of bisphosphonates for recurrences of tumor-induced hypercalcemia. Support Care Cancer 2000;8:398-404.
4. Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcemia. Lancet 1993;341: 1611-3.
5. Endo K, Katsumata K, Iguchi H, et al. Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia. J Bone Miner Res 1998;13:1378-83.
6. Endo K, Ichikawa F, Uchiyama Y, etal. Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effects of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J Biol Chem 1994;269:32693-9.
7. Mundy GR, Martin TJ. The hypercalcemia of malignancy: pathogenesis and management. Metabolism 1982;31:1247-77.
8. Mundy GR, Guise TA. Role of parathyroid hormone-related peptide in hypercalcemia of malignancy and osteolytic bone disease. Endocr Relat Cancer 1998; 5:15-26.
9. Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science 1991; 254:1024-6.
10. Mundy GR, Guise TA. Hypercalcemia of malignancy Am J Med 1997;103:134-45.
11. Syed MA, Horwitz MJ, Tedesco MB, Garcia-Ocana A, Wisniewski SR, Stewart AF. Parathyroid hormone-related protein-(1-36) stimulates renal tubular calcium reabsorption in normal human volunteers: implications for the pathogenesis of humoral hypercalcemia of malignancy. J Clin Endocrinol Metab 2001;86:1525-31.
12. Kukreja SC, Shevrin DH, Wimbiscus SA, et al. Antibodies to parathyroid hormone-related protein lower serum calcium in athymic mouse models of malignancy-associated hypercalcemia due to human tumors. J Clin Invest 1988;82:1798-802.
13. Sato K, Yamakawa Y, Shizume, K, et al. Passive immunization with anti-parathyroid hormone-related protein monoclonal antibody markedly prolongs survival time of hypercalcemic nude mice bearing transplanted human PTHrP-producing tumors. J Bone Miner Res 1993;8:849-60.
14. Onuma E, Sato K, Saito H, et al. Generation of a humanized monoclonal antibody against human parathyroid hormone-related protein and its efficacy against humoral hypercalcemia of malignancy. Anticancer Res 2004;24:2665-74.
15. Brown EM. Homeostatic mechanisms regulating extracellular and intracellular calcium metabolism. In: Bilezikian JP, Marcus R, Levine MA, editors. The parathyroids, basic and clinical concepts. New York: Raven Press; 1994. p. 15-52.
16. Guise TA, Mundy GR. Cancer and bone. Endocr Rev 1998;19:18-54.
17. Strewler GJ, Nissenson RA. Skeletal and renal actions of parathyroid hormone-related protein. In. Bilezikian JP Marcus R, Levine MA, editors. The parathyroids, basic and clinical concepts. New York: Raven Press; 1994. p. 311-20.
18. Sartori L, Insogna KL, Barrett PQ. Renal phosphate transport in humoral hypercalcemia of malignancy. Am J Physiol 1988;255:F1078-84.